2009
DOI: 10.1007/s00467-009-1356-x
|View full text |Cite
|
Sign up to set email alerts
|

Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome

Abstract: The purpose of this study was to assess the results of therapy with mycophenolate mofetil (MMF) in children with idiopathic nephrotic syndrome (INS) who were both steroid- and cyclophosphamide-resistant. Treatment lasted a minimum of 6 months, and follow-up data were collected over a 2-year period. The children were divided into two groups: Group 1 (n=34) comprised patients who had received cyclosporine A (CsA) before the initiation of MMF therapy; Group 2 (n=18) comprised patients who received only MMF. Among… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
14
0
2

Year Published

2011
2011
2019
2019

Publication Types

Select...
5
5

Relationship

0
10

Authors

Journals

citations
Cited by 41 publications
(19 citation statements)
references
References 25 publications
0
14
0
2
Order By: Relevance
“…Preliminary data raise the question of whether underexposure may result in relapses [35]. To date, the side effects of mycophenolate may be underreported: for example, de Mello et al [36] report severe gastrointestinal complications in some of their patients and the death of one of these patients, but they do not mention this side effect in the abstract.…”
Section: Mycophenolic Acidmentioning
confidence: 96%
“…Preliminary data raise the question of whether underexposure may result in relapses [35]. To date, the side effects of mycophenolate may be underreported: for example, de Mello et al [36] report severe gastrointestinal complications in some of their patients and the death of one of these patients, but they do not mention this side effect in the abstract.…”
Section: Mycophenolic Acidmentioning
confidence: 96%
“…Recently, MMF has been a commonly used steroid-sparing agent in childhood NS. In patients with SRNS, MMF gave rise to complete remission in 23-62% of patients and partial remission in 25-37% of patients (21)(22)(23). In our study, we used MMF with a mean duration of 26 months (10-44 months) and complete remission was achieved in 50% of patients.…”
Section: Discussionmentioning
confidence: 99%
“…Dilaporkan pada pemberian MMF selama minimal 6 bulan menghasilkan remisi komplit 23%-62%, remisi partial 25%-37%, dan tanpa remisi 8%-40%. 31 Apabila pasien sindrom nefrotik steroid resisten mengalami relaps kembali setelah pengobatan maka dianjurkan diberikan preparat kortikosteroid oral (2D) seperti pengobatan relaps, pada umumnya remisi cepat tercapai. Dapat juga kembali ke imunosupresan yang sebelumnya (2D), kecuali jika dipergunakan CPA untuk menghindari efek kumulatif (2D), atau menggantikan dengan obat imunupresan yang lain.…”
Section: Pengobatan Steroid Resisten Primer/ Sekunderunclassified